RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. Combining hyperthermia with chemotherapy may kill more tumor cells. It is not yet known if chemotherapy is more effective with or without whole-body hyperthermia therapy in treating <a target="_blank" href="https://clinicaltrials.gov/study/NCT00045461">gynecologic cancer</a>.
PURPOSE: Randomized phase II/III trial to compare the effectiveness of chemotherapy with or without whole-body hyperthermia in treating patients who have recurrent ovarian epithelial, fallopian tube, or <a target="_blank" href="https://clinicaltrials.gov/study/NCT00045461">peritoneal cancer</a>.
OBJECTIVES:
<ul>
<li>Compare the time to progressive disease in patients with recurrent ovarian epithelial, fallopian tube, or extraovarian peritoneal cancer treated with carboplatin and ifosfamide with or without whole body hyperthermia.
</li>
<li>Compare the response rate, duration of response, and survival time of patients treated with these regimens.
</li>
<li>Compare the effect on the presence of disseminated tumor cells in bone marrow in patients treated with these regimens.
</li>
<li>Compare the toxicity of these regimens in these patients.
</li>
<li>Assess quality of life of patients treated with these regimens.
</li>
</ul>

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. Combining hyperthermia with chemotherapy may kill more tumor cells. It is not yet known if chemotherapy is more effective with or without whole-body hyperthermia therapy in treating [gynecologic cancer](https://clinicaltrials.gov/study/NCT00045461).

PURPOSE: Randomized phase II/III trial to compare the effectiveness of chemotherapy with or without whole-body hyperthermia in treating patients who have recurrent ovarian epithelial, fallopian tube, or [peritoneal cancer](https://clinicaltrials.gov/study/NCT00045461).

**OBJECTIVES**:

* Compare the time to progressive disease in patients with recurrent ovarian epithelial, fallopian tube, or extraovarian peritoneal cancer treated with carboplatin and ifosfamide with or without whole body hyperthermia.
    
* Compare the response rate, duration of response, and survival time of patients treated with these regimens.
    
* Compare the effect on the presence of disseminated tumor cells in bone marrow in patients treated with these regimens.
    
* Compare the toxicity of these regimens in these patients.
    
* Assess quality of life of patients treated with these regimens.

Metastatic Breast Cancer by Circulating Tumor DNA